Treatment of metastatic carcinoid tumours with alpha-interferon;TRAITEMENT DES TUMEURS CARCINOIDES METASTATIQUES PAR INTERFERON ALPHA

Presse Medicale

Volumn 25, Issue 2, 1996, Pages 63-67

  Votte, A ^a   Iglicki, F ^a   Sevenet F ^a   Tabah, I ^b   Dupas, J L ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b Laboratoires Schering Plough   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; RECOMBINANT ALPHA2B INTERFERON; SEROTONIN; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CARCINOID; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; MALE; METASTASIS; MIDDLE AGED; REVIEW; TIME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOID TUMOR; FEMALE; HUMANS; INTERFERON ALFA-2B; INTERFERON-ALPHA; MALE; MIDDLE AGED; TIME FACTORS;

EID: 0030594070     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Norheim I, Oberg K, Theodorsson-Norheim E, Lindgren PG, Lundqvist G, Magnusson P. Malignant carcinoid tumors. Ann Surg 1987 ; 206:115-26.
2. Kvols LK. Therapy of the malignant carcinoid syndrome. Endocrinol Metab Clin North Am 1989 ; 18:557-68.
3. Godwin JD. Carcinoid tumors. An analysis of 2837 cases. Cancer 1975 ; 36:560-9.
4. De Vries EGE, Kema IP, Sloof MJH et al Recent developments in diagnosis and treatment of metastatic carcinoid tumours. Scand J Gastroenterol 1993 ; 28:87-93.
5. Kvols LK, Moertel CG, O'Connel MJ, Schutt AJ, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long acting somatostatin analogue. N Engl J Med 1986 ; 315:663-6.
6. Ruszniewski P, Ducreux M, Michel H et al. Traitement prolongé du syndrome carcinoïde par le lanréotide : résultais d'une étude prospective multicentrique (résumé). Gastroenterol Clin Biol 1994 ; 18:A7.
7. Oberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983 ; 309:129-33.
8. Ruszniewski P, Rougier P, Roche A. Hepatic arterial chimioembolization in patients with liver metastases of endocrine tumors. Cancer 1993 ; 71:2624-30.
9. Elias D, Rougier Ph, Lasser Ph et al Chirurgie majeure et chimiothérapie réductionnelle dans les apudomes métastatiques. Ann Chir 1988 ; 42:474-81.
10. Alsina AE, Bartus S, Hull D, Rosson R, Schweizer RT. Liver transplant for metastatic neuroendocrine tumor. J Clin Gastroenterol 1990 ; 12:533-7.
11. Starzl TE, Todo S, Tzakis A et al. Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg 1989 ; 210:374-86.
12. Oberg K, Norheim I, Lind E et al. Treatment of malignant carcinoid tumors with human leukocyte interferon. Long-term results. Cancer Treat Rep 1986 ; 70:1297-304.
13. Oberg K, Eriksson B. Medical treatment of neuroendocrine gut and pancreatic tumors. Acta Oncol 1989 ; 28:425-31.
14. Nobin A, Lindblom A, Mannson B, Sundberg M. Interferon treatment in patients with malignant carcinoids. Acta Oncol 1989 ; 28:445-9.
15. Hanssen LE, Schrumpf E, Kolbenstvedt AN, Tausjo J, Dolva LO. Treatment of malignant metastatic midgut carcinoid tumours with recombinant human alpha 2b interferon with or without prior hepatic artery embolization. Scand J Gastroenterol 1989 ; 24:787-95.
16. Tiensuu-Janson E, Rönnblom L, Ahlström H et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozotocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 1992 ; 3:635-8.
17. Oberg K, Eriksson B. The role of interferon in the management of carcinoid tumors. Acta Oncol 1991 ; 30:519-22.
18. Basser KL, Lieschke GJ, Sheridan WP, Fox RM, Green MD. Recombinant alpha 2b interferon in patients with malignant carcinoid tumour. Aust NZ J Med 1991 ; 21:875-8.
19. Bajetta E, Zilembo N, Di Bartolemeo M et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferes alpha-2a. Cancer 1993 ; 72:3099-105.
20. Valimäki M, Järvinen K, Salmela P, Sane T, Sjöblom SM, Pelkonen R. Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 1991 ; 67 547-9.
21. Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 1989 ; 7:865-8.
22. Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1983 ; 1:727-40.
23. Moertel CG. An odyssey in the land of small tumors. J Clin Oncol 1987 ; 5.1503-22.
24. Oberg K, Norheim I, Theodorsson E. Treatment of malignant midgut carcinoid rumours with a long-acting somatostatin analogue octreotide. Acta Oncol 1991 ; 30 503-7.
25. Saltz L, Trochanowski B, Buckley M et al. Octreotide as an antincoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors Cancer 1993 ; 72:244-8.
26. Gresser IA. Antitumor effects of interferon. Acta Oncol 1989 ; 28:347-53.
27. Oberg K. Endocrine tumors of the gastrointestinal tract: systemic treatment. Anticancer-Drugs 1994 ; 5:503-19.
28. Saltz L, Kemeny N, Schwartz G, Keisen D. A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer 1994 ; 74:958-61
29. Tiensuu-Janson EM, Ahlstrom H, Anderson T, Oberg K. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 1992 ; 28a:1647-50.
30. Hajarizadeh H, Ivanceo K, Mueller CR, Fletcher WS, Woltering EA. Effective palliative treatment of metastatic carcinoid tumors with intra-artenal chemotherapy/chemoembolization combined with octreotide acetate. Am J Surg 1992 ; 163:479-83